Every material Form 8-K Eikon Therapeutics, Inc. has filed with the SEC since August 13, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Eikon Therapeutics presented updated data from its Phase 2 TeLuRide-005 trial of EIK1001 with pembrolizumab and chemotherapy at the 2026 ESMO Congress, in 72 patients with previously untreated stage 4 non-small cell lung cancer. The filing reports a 63.1% pooled objective response rate and 48.6% rate of Grade 3 or higher treatment-related adverse events, with no new financial results. The data are a clinical update that does not change the company's reported financials, but they set the outlook for its Phase 2/3 TeLuRide-008 trial, with a dose-selection interim analysis expected in the second half of 2027.
Pooled objective response rate of 63.1% and disease control rate of 89.2% in 65 efficacy-evaluable participants, at an October 1, 2026 data cutoff
Squamous cohort objective response rate of 72.4% and median duration of response of 12.9 months; non-squamous cohort objective response rate of 55.6%
Grade 3 or higher treatment-related adverse events occurred in 48.6% of participants, and 6.9% discontinued treatment due to them
Interim analysis to select the single EIK1001 dose for TeLuRide-008 is expected in the second half of 2027
Eikon Therapeutics presented updated and initial clinical data from its PARP1 and WRN helicase programs at the 2026 ESMO Congress on October 23, 2026, and issued a press release on the results. The filing reports objective response rates alongside frequent Grade 3 or higher adverse events, and it contains no financial results, so the effect on shareholders is mixed and depends on later development steps.
EIK1003 Cohort 1C with weekly paclitaxel: objective response rate 26.4% (14/53); Grade 3 or higher adverse events in 80.3% (49/61) of participants
EIK1003 monotherapy Cohort 1A: objective response rate 14.3% (7/49) among efficacy-evaluable participants, with data cutoff October 1, 2026
EIK1004 monotherapy: objective response rate 12.1% (7/58); Grade 3 or higher adverse events in 17.6% (12/68) of participants
Further EIK1003 Cohort 1D and EIK1004 docetaxel combination results are expected in the second half of 2027
On August 13, 2026, Eikon Therapeutics furnished an updated corporate presentation as Exhibit 99.1 to a Form 8-K under Regulation FD. The deck restates clinical data and pipeline timelines, including 2H 2026 Phase 2 data readouts for EIK1001 and an IND submission for EIK1006 projected by the end of 2026. The filing contains no financial results, guidance, or transaction terms.
Updated corporate presentation, labeled Q3 Company Update August 2026, furnished as Exhibit 99.1 and not deemed filed under the Exchange Act.
EIK1001 TeLuRide-005 nonsquamous NSCLC cohort showed an objective response rate of 55.6% (N=36 efficacy evaluable), with data as of May 4, 2026, presented at ASCO 2026.
EIK1003 monotherapy showed a 14.3% objective response rate (7/49), and 24.5% (13/53) in combination with paclitaxel, in Phase 1/2 data as of May 4, 2026.
EIK1006 (AR) IND submission is projected by the end of 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Eikon Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →